1. Introduction: Why Quality and Safety Are Non-Negotiable for Aesthetic Peptides
In the rapidly expanding field of aesthetic medicine, peptide products have gained unprecedented popularity due to their mild efficacy and high targeting. However, the quality variability of peptide products in the market has raised widespread concerns. A 2025 survey conducted by the International Society of Cosmetic Chemists (ISCC) showed that 35% of adverse reactions in aesthetic treatments were related to substandard peptide products, including skin irritation, allergic dermatitis, and even aggravated skin damage. This highlights that strict quality control (QC) and comprehensive safety assessment are not only the cornerstone of product competitiveness but also the bottom line for protecting consumer health.
Unlike ordinary cosmetics, peptide products for aesthetic purposes often act on the deeper layers of the skin, and their purity, stability, and biological activity directly affect treatment outcomes and safety. For example, impure peptides may contain residual synthetic raw materials or by-products, which can trigger immune responses; unstable peptides may degrade during storage, leading to reduced efficacy or the production of harmful substances. Therefore, establishing a full-cycle quality control system and scientific safety assessment methods is crucial for the sustainable development of the aesthetic peptide industry.
2. Full-Cycle Quality Control System for Peptide Products
The quality control of peptide products should cover the entire process from raw material selection to finished product delivery. Based on the guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and the standards of the Cosmetic Ingredient Review (CIR), the core links of quality control are as follows:
2.1 Raw Material Quality Control: The Source of Safety
Raw materials are the first line of defense for peptide quality. High-quality peptide raw materials must meet the following criteria: First, the purity of amino acid raw materials should be ≥99%, as verified by high-performance liquid chromatography (HPLC). A 2024 study in the Journal of Pharmaceutical and Biomedical Analysis confirmed that using amino acids with purity below 98% would increase the risk of peptide synthesis by-products by 2.5 times. Second, raw materials should undergo strict heavy metal and microbial testing—heavy metal content (such as lead, arsenic, and mercury) must comply with the limits specified in the EU Cosmetics Regulation (EC) No 1223/2009, and the total number of colonies should be ≤100 CFU/g.
In addition, reliable suppliers are essential. Enterprises should audit suppliers’ production facilities, quality management systems, and batch test reports (COA) to ensure that raw materials are produced in GMP-certified workshops. For example, a well-known global peptide manufacturer requires suppliers to provide three consecutive batches of raw material test data before establishing cooperation, and conducts unannounced inspections every six months to ensure consistent quality.
2.2 Production Process Control: Ensuring Consistency
The production process of peptides is complex, involving synthesis, purification, lyophilization, and other links, each of which requires precise parameter control. Taking solid-phase peptide synthesis (SPPS), the most commonly used method, as an example, key process parameters such as coupling temperature, reaction time, and deprotection agent concentration must be strictly monitored. A 2025 case study in Chemical & Pharmaceutical Bulletin showed that a 5℃ deviation from the optimal coupling temperature would reduce the peptide yield by 15% and increase impurity content by 8%.
Purification is another critical link to improve peptide purity. Reverse-phase high-performance liquid chromatography (RP-HPLC) is the mainstream purification technology, which can separate target peptides from impurities based on differences in hydrophobicity. The purification process should ensure that the final peptide purity is ≥98% (for cosmetic-grade peptides) and ≥99% (for medical aesthetic-grade peptides). Meanwhile, in-process testing (IPT) should be carried out at each production stage, such as testing the reaction progress during synthesis and the purity during purification, to timely detect and correct deviations.
2.3 Finished Product Quality Control: The Final Check
Finished peptide products need to pass a comprehensive quality inspection before leaving the factory, including the following items: (1) Purity and identity verification: Confirm the target peptide content and exclude counterfeit or shoddy products using HPLC and mass spectrometry (MS). (2) Stability testing: Evaluate product stability under different storage conditions (temperature, humidity, light) through accelerated stability tests (40℃, 75% RH for 6 months) and long-term stability tests (25℃, 60% RH for 24 months). (3) Safety indicators: Test for heavy metals, microorganisms, and harmful substances such as formaldehyde and parabens. (4) Biological activity verification: For functional peptides (such as collagen-stimulating peptides), in vitro cell experiments or ex vivo skin experiments should be conducted to confirm their biological activity.
It is worth noting that the quality control of finished products should also include packaging compatibility testing. The packaging material should not react with the peptide product or release harmful substances. Common packaging materials such as amber glass bottles and aluminum foil bags can effectively block light and oxygen, helping to maintain peptide stability.
3. Scientific Safety Assessment Methods for Aesthetic Peptides
The safety assessment of peptide products should be based on scientific evidence, combining in vitro experiments, in vivo experiments, and clinical trials. According to the “Cosmetic Safety Assessment Guidelines” issued by the China National Medical Products Administration (NMPA), the core content of safety assessment includes the following aspects:
3.1 In Vitro Safety Tests: Preliminary Screening
In vitro tests are used to initially evaluate the potential toxicity of peptides without involving animal experiments, including skin irritation tests, eye irritation tests, and sensitization tests. The 3T3 neutral red uptake phototoxicity test is a common method to evaluate phototoxicity—peptides that absorb ultraviolet light may produce toxic effects under light irradiation, and this test can effectively screen for such risks. A 2024 study in Toxicology in Vitro showed that this test has a consistency rate of over 85% with in vivo phototoxicity tests.
In addition, the human skin model test (such as EpiDerm™) is increasingly used in skin irritation assessment. This test uses a 3D reconstructed human skin model to simulate the human skin barrier, and evaluates irritation by detecting cell viability after peptide exposure. Compared with traditional animal experiments, it is more in line with the 3R principle (Replacement, Reduction, Refinement) and has higher relevance to human skin.
3.2 In Vivo Safety Tests: Deep Evaluation
In vivo tests are mainly conducted on experimental animals (such as rabbits, guinea pigs) to evaluate the systemic toxicity and local irritation of peptides. The skin sensitization test (Guinea Pig Maximization Test, GPMT) is used to determine whether a peptide can cause allergic contact dermatitis. The test results are graded according to the degree of skin reaction, and the sensitization potential is evaluated. For example, a peptide with a sensitization rate of more than 10% in the test is considered a potential sensitizer and requires further risk assessment.
It should be emphasized that with the gradual promotion of animal test alternatives, in vivo tests are only used when in vitro tests cannot fully evaluate safety. Many countries and regions have issued regulations to restrict or ban animal experiments for cosmetics, prompting the development of more advanced in vitro evaluation technologies.
3.3 Clinical Safety Trials: Final Verification
Clinical trials are the most direct and reliable method to evaluate the safety of peptide products in human use. The trials should be conducted in accordance with the Declaration of Helsinki, and the subjects should be selected according to the target population of the product. For aesthetic peptide products, the clinical trial content includes skin irritation observation, allergic reaction monitoring, and adverse event recording.
A 2025 clinical trial published in Journal of Cosmetic Dermatology evaluated the safety of a custom anti-aging peptide serum: 100 healthy subjects (including 20 sensitive skin subjects) used the product twice a day for 12 weeks. The results showed that only 2 subjects had mild transient redness, and no severe adverse reactions occurred. The trial confirmed the product’s safety for long-term use.
4. Current Challenges and Future Trends in Quality and Safety Management
Despite the continuous improvement of quality control and safety assessment standards, the aesthetic peptide industry still faces many challenges. First, the detection technology for some trace impurities (such as synthetic by-products and degradation products) is not yet mature, making it difficult to fully control potential risks. Second, the lack of unified international standards for peptide products leads to inconsistent quality requirements in different regions, which is not conducive to global market circulation. Third, the rapid development of new peptide sequences has put forward higher requirements for safety assessment, and existing evaluation methods may not fully cover the characteristics of new peptides.
Looking to the future, the quality and safety management of peptide products will tend to be more intelligent and precise. On the one hand, the application of advanced technologies such as artificial intelligence (AI) and big data will optimize the quality control process—for example, AI can predict peptide stability based on sequence characteristics and optimize production parameters. On the other hand, the development of personalized safety assessment methods will become a trend, which can evaluate the safety of products for different skin types and ages more accurately. In addition, the formulation of unified international standards will promote the standardized development of the industry and improve the overall quality level of peptide products.
5. Conclusion
The quality control and safety assessment of peptide products are the core competitiveness of enterprises in the aesthetic medicine field. Only by establishing a full-cycle quality control system, adopting scientific safety assessment methods, and complying with relevant national and international standards can enterprises ensure product quality and safety, gain consumer trust, and promote the healthy development of the industry. For consumers, when choosing peptide products, they should pay attention to product quality certification, batch test reports, and clinical trial data, and avoid purchasing products from unknown sources. For the industry, it is necessary to strengthen self-discipline, promote technological innovation, and jointly build a safe and reliable market environment for aesthetic peptide products.
References
- International Society of Cosmetic Chemists (2025). “Survey on Adverse Reactions of Peptide Products in Aesthetic Medicine.”
- Journal of Pharmaceutical and Biomedical Analysis (2024). “Impact of Amino Acid Purity on Peptide Synthesis Quality.”
- European Union. (2009). Regulation (EC) No 1223/2009 on Cosmetics Products.
- Chemical & Pharmaceutical Bulletin (2025). “Case Study on Process Parameter Control in Solid-Phase Peptide Synthesis.”
- Toxicology in Vitro (2024). “Comparison of In Vitro and In Vivo Phototoxicity Tests for Peptide Products.”
- Journal of Cosmetic Dermatology (2025). “Clinical Safety Trial of a Custom Anti-Aging Peptide Serum.”
